Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL8743763 | 0.89 | OTC (0.51) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL31181943 | 0.88 | OTC (0.43) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL15110976 | 0.86 | OTC (0.39) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL31663499 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL7928810 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL30361345 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1791 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL2411547 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1790 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL288132 | 0.84 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145464-A2 | IBOGAINE AND NORIBOGAINE PRODRUGS AND METHODS OF USE | ATAI THERAPEUTICS, INC: (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145462-A1 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | ATAI THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20240210412-A1 | SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024130140-A2 | PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF | ATAI THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-12012381-B2 | Dimethyltryptamine analogues as nitric oxide delivery drugs | ATAI THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-06-13 | — | — | US | disclosed |
| US-11993577-B2 | Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers | EMPATHBIO, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024102845-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-1871420-A2 | METHODS OF FACILITATING CELL SURVIVAL USING NEUROTROPHIN MIMETICS | The University of North Carolina at Chapel Hill (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070060526-A1 | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| WO-2006133353-A2 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING NON-PEPTIDE AND PEPTIDE BDNF NEUROTROPHIN MIMETICS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060246072-A1 | relieving or causing regression of Alzheimer's disease comprising administering compounds having binding specificity for a p75NTR receptor molecule to treat neurodegenerative disorders | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-11-02 | — | — | US | disclosed |
| WO-2006113097-A2 | METHODS OF FACILITATING CELL SURVIVAL USING NEUROTROPHIN MIMETICS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-10-26 | — | — | WO | disclosed |
| US-6939884-B2 | Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof | NOVACTYL, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1406659-A1 | PHARMACEUTICAL AGENTS CONTAINING ACYCLOVIR, FUSARIC ACID AND DERIVATIVES THEREOF | Novactyl, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030139370-A1 | Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof | NOVACTYL, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6569864-B1 | 1.75 mu M of acyclovir and 1 mu g/ml of fusaric acid; viricides | NOVACTYL, INC. | 2003-05-27 | — | — | US | disclosed |
| WO-2003006062-A1 | PHARMACEUTICAL AGENTS CONTAINING ACYCLOVIR, FUSARIC ACID AND DERIVATIVES THEREOF | NOVACTYL, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | COMT, PNMT, DDT | OTC 1974/4885DDAH1 216/4885NOS2 3122/4885 |
| US-20240210412-A1 | SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2 | PTGDR2, PTGFR, PTGDR | OTC 4520/4885DDAH1 1709/4885NOS2 345/4885 |
| US-11993577-B2 | Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers | HTR3A, HTR3B, HTR3C | OTC 3400/4885DDAH1 278/4885NOS2 2827/4885 |
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RXFP3, RXFP1, RXFP4 | OTC 2400/4885DDAH1 4282/4885NOS2 1835/4885 |
| US-12012381-B2 | Dimethyltryptamine analogues as nitric oxide delivery drugs | NOS2, NOS1, NOS3 | OTC 386/4885DDAH1 303/4885NOS2 1/4885 |
| US-20070060526-A1 | Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics | BDNF, NTRK2, NGF | OTC 1938/4885DDAH1 3967/4885NOS2 1878/4885 |
| US-20030139370-A1 | Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof | FUS, UMPS, PNP | OTC 66/4885DDAH1 1755/4885NOS2 2951/4885 |
| US-20060246072-A1 | relieving or causing regression of Alzheimer's disease comprising administering compounds having binding specificity for a p75NTR receptor molecule to treat neurodegenerative disorders | NGF, NGFR, GAP43 | OTC 723/4885DDAH1 2594/4885NOS2 1224/4885 |
| US-20240190921-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | MYD88, CD74, IRF3 | OTC 2468/4885DDAH1 2975/4885NOS2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.